Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS)

Inclusion Criteria

• •Intermediate or High grade (AJCC 7th edition Grade 3 and 4 or Grade 2 and 3 of a 3 tier system) STS as determined by local pathology diagnostic biopsy specimen review
• •Musculoskeletal tumor in extremities, trunk or chest wall
• •Primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter as measured by Response Evaluation Criteria In Solid Tumors (RECIST) criteria v1.1
• •Clinical Stage T2N0M0 (AJCC 7th edition)
• •Age ≥18 years at time of consent
• •Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0 or 1
• •Patient's written study specific, Institutional Review Board (IRB) stamped informed consent.
• •Adequate organ function (measured within a week prior to beginning treatment for Arm B and within 2 weeks of beginning treatment for Arm A): white blood count (WBC) \> 3,000/mm³ and absolute neutrophil count (ANC) \>1500/mm³; Platelets \> 100,000/mm³; Hematocrit \> 25%; Bilirubin \< 2.0 mg/dL; Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min
• •Radiation Oncologist must confirm that a 2-3 cm strip of skin can be spared from RT.